Innovative MulticOmponent Drug dEsign (IMODE) for enhancing regional strategic advantages in pharmaceutical and biomedical applications | 2 Mers Seas Zeeën

IMODE

You are here

Innovative MulticOmponent Drug dEsign (IMODE) for enhancing regional strategic advantages in pharmaceutical and biomedical applications

Priority Axis

Technological and Social Innovation

Specific objective

Technological Innovation

Lead partner

University Lille 1 - Unité Matériaux et Transformations

Contact

Start Date

01/07/2016

End Date

30/06/2020

Project budget

5 960 060

ERDF amount

3 576 036

ERDF rate

60%

    About

    Common challenge

    The IMODE project is motivated by an unmet need for developing solutions to address societal challenges for improved healthcare, novel medicines while maintaining low medical costs. This will be achieved with the collaboration of academic research groups and SMEs through a transdisciplinary applied research programme in materials science, pharmacy, biology and medicine. The project will strengthen innovation in the 2 Seas Area in order to obtain a strategic advantage for novel pharmaceutical and medical applications bridging the current gap between academia and the private sector.

    Main Achievements

    The objective of IMODE is to enhance R&D on major societal challenges for improved healthcare by developing solutions for novel pharmaceutical products and medical devices through new multicomponent drug systems. It is based on the international joint collaboration between academic research groups, SMEs, one large company and one economic development agency.

    After 30 months of implementation, IMODE is on track. All research, technology transfer, training and communications activities are progressing very well. Among the 17 deliverables expected in 2018 (No output was expected): 14 were actually delivered. This good result originates from the close fruitful collaboration between the different partners. The cross border’s project dimension is demonstrated by frequent meetings, exchange of staffs, common publications and presentations,…etc between the different partners. 

    Very interesting results have been obtained to cite only a few:

    • New methodology for the drug-excipient compatibility and co-crystal screening using ultra-low quantity of the sample required (1/1000 of the conventional method) and faster speed (40 times faster than the conventional method),
    • New continuous extrusion granulation process to be adopted by pharma industry. The filling of a new patent (not originally planned) will be exploited,
    • New polymer-based stents has been designed and prepared by 3D printing. They can be used for the release of antiproliferative drugs. 3D printed stents present excellent mechanical properties that allows to retain the arteries open for the required time. 

    2 training schools have been organized by IMODE partners on controlled Drug delivery systems, treatment of cardiovascular diseases, design of medical devices and physical states and transformations of drugs. Both training schools have gathered about 30 participants (master students, PhDs, young researchers, technical staffs,..) at the University of Lille (France) and the University of East-Anglia (UK) and were particularly successful. 

    Several prospections actions were made during MedFit 2018 and Partners also had several direct discussion meetings with companies (SMEs, big pharma) about IMODE achievements during internationals events.

    To increase the visibility of the cross border IMODE project: one dissemination workshop with stakeholder and B2B meetings was organized in Lille in the framework of the BIOFIT2018 event and 2 newsletters were also sent in February and in June 2018.

    Partnership

    Partners

    University College London, UCL School of Pharmacy

    Université Lille 2 Droit et Santé

    Universiteit Gent Laboratory of Pharmaceutical Technology

    University of East Anglia

    ImaBiotech

    University of Greenwich

    G.I.E Eurasanté

    Ashford and St Peter's Hospital's NHS Foundation Trust

    Cubic Pharmaceuticals Limited

    Roquette Frères